NCT05178654 is a Phase 1 clinical trial of [14C]PF-07321332 in Healthy Participants, sponsored by Pfizer.

Who is sponsoring NCT05178654?

NCT05178654 is sponsored by Pfizer.

What drugs are being tested in NCT05178654?

Interventions in NCT05178654: [14C]PF-07321332.

What condition does NCT05178654 study?

NCT05178654 studies Healthy Participants.

Is NCT05178654 still recruiting?

NCT05178654 is currently withdrawn. Last updated 31 January 2022.

Last reviewed 2022-01-31 · How we verify

NCT05178654

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Withdrawn Phase 1 Last updated 31 January 2022

What this trial tests

Phase 1 trial testing [14C]PF-07321332 in Healthy Participants. Withdrawn.

Timeline

22 February 2022

Primary endpoint
1 April 2022

1 April 2022

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	basic science
Start date	22 February 2022
Primary completion	1 April 2022
Estimated completion	1 April 2022

Drugs / interventions tested

[14C]PF-07321332 — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, male only, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled \[14C\]PF-07321332 in healthy male participants following oral administration with ritonavir.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL, Finch N. · · 2022 · cited 30× · PMID 35862759 · DOI 10.1128/aac.02404-21

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05178654 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 31 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05178654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing